OTCMKTS:HYPMY

Hypera (HYPMY) Stock Price, News & Analysis

$5.83
-0.09 (-1.52%)
(As of 05/10/2024 ET)
Today's Range
$5.83
$5.87
50-Day Range
$5.29
$7.00
52-Week Range
$5.19
$10.08
Volume
3,428 shs
Average Volume
10,741 shs
Market Capitalization
$3.69 billion
P/E Ratio
N/A
Dividend Yield
3.09%
Price Target
N/A
HYPMY stock logo

About Hypera Stock (OTCMKTS:HYPMY)

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

HYPMY Stock Price History

HYPMY Stock News Headlines

READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Hypera SA's Dividend Analysis
Hypera SA ADR HYPMY
HYPMY Hypera S.A.
Hypera S.A. goes ex dividend tomorrow
Sree Rayalaseema Hi-Strength Hypo Ltd.
Hypera Shares Fall 7.2% After Soft 3Q Earnings
Hypera S.A. (HYPE3.SA)
Hypera S.A. (HYPMY)
See More Headlines
Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/26/2024
Today
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:HYPMY
Fax
N/A
Employees
10,783
Year Founded
N/A

Profitability

Net Income
$330.11 million
Pretax Margin
20.24%

Debt

Sales & Book Value

Annual Sales
$1.59 billion
Cash Flow
$0.57 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.75 billion
Optionable
Not Optionable
Beta
1.00
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Breno Toledo Pires de Oliveira
    CEO & Director
  • Mr. Adalmario Ghovatto Satheler do Couto
    Investor Relations Officer & CFO
  • Mr. Carlos Roberto Scorsi (Age 62)
    Chief Operating officer
  • Juliana Aguinaga Damião Salem
    Senior Legal Officer & Director
  • Joao Felipe Khamis Aguilar
    Risks & Compliance Officer
  • Mr. Luiz Eduardo Sales Clavis
    VP of Sales and Marketing & Director
  • Mauricio Christovam
    Senior Human Resources Officer
  • Mr. Hélio Segouras
    Head of Consumer Health

HYPMY Stock Analysis - Frequently Asked Questions

How have HYPMY shares performed in 2024?

Hypera's stock was trading at $7.16 at the beginning of the year. Since then, HYPMY stock has decreased by 18.6% and is now trading at $5.8260.
View the best growth stocks for 2024 here
.

Are investors shorting Hypera?

Hypera saw a drop in short interest in April. As of April 15th, there was short interest totaling 1,900 shares, a drop of 89.1% from the March 31st total of 17,400 shares. Based on an average daily trading volume, of 18,000 shares, the short-interest ratio is currently 0.1 days.
View Hypera's Short Interest
.

How were Hypera's earnings last quarter?

Hypera S.A. (OTCMKTS:HYPMY) issued its quarterly earnings results on Friday, April, 26th. The company reported $0.12 earnings per share for the quarter. The firm had revenue of $368.97 million for the quarter. Hypera had a trailing twelve-month return on equity of 16.14% and a net margin of 21.68%.

Is Hypera a good dividend stock?

Hypera (OTCMKTS:HYPMY) pays an annual dividend of $0.18 per share and currently has a dividend yield of 3.06%.
Read our dividend analysis for HYPMY.

How do I buy shares of Hypera?

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HYPMY) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners